STAT3 and cardiac hypertrophy: They demonstrated that intravenous administration of HHP-Exo significantly improved cardiac function in a mouse model of TAC-induced cardiac hypertrophy and HF, and that HHP-Exo reduced left ventricular hypertrophy more than control exosomes (CON-Exos) by inhibiting p-STAT3, p-ERK1/2, β-MHC, BNP, GP130, and p-AKT [132].